ATE487487T1 - Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämie - Google Patents

Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämie

Info

Publication number
ATE487487T1
ATE487487T1 AT07301337T AT07301337T ATE487487T1 AT E487487 T1 ATE487487 T1 AT E487487T1 AT 07301337 T AT07301337 T AT 07301337T AT 07301337 T AT07301337 T AT 07301337T AT E487487 T1 ATE487487 T1 AT E487487T1
Authority
AT
Austria
Prior art keywords
nucleolin
preventing
interaction
compounds
prevent
Prior art date
Application number
AT07301337T
Other languages
English (en)
Inventor
Monique Barel
Malades Enfants
Alain- Charbit
Ara Hovanessian
Jean-Paul Briand
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE487487T1 publication Critical patent/ATE487487T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07301337T 2007-09-04 2007-09-04 Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämie ATE487487T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07301337A EP2033655B1 (de) 2007-09-04 2007-09-04 Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie

Publications (1)

Publication Number Publication Date
ATE487487T1 true ATE487487T1 (de) 2010-11-15

Family

ID=39032196

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07301337T ATE487487T1 (de) 2007-09-04 2007-09-04 Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämie

Country Status (3)

Country Link
EP (1) EP2033655B1 (de)
AT (1) ATE487487T1 (de)
DE (1) DE602007010459D1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900341B1 (fr) 2006-04-27 2012-09-14 Centre Nat Rech Scient Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
AU2008356840B2 (en) 2008-05-22 2013-05-16 Centre National De La Recherche Scientifique (Cnrs) New optically pure compounds for improved therapeutic efficiency
CA2813646A1 (en) * 2010-10-04 2012-04-12 Robert Zimmer Multivalent synthetic compounds as antibiotic treatment
US9625466B2 (en) 2011-04-06 2017-04-18 Cornell University Signal amplification methods for the imaging of protein synthesis and neurotransmitter transport
CN103196877B (zh) * 2013-03-08 2015-06-03 刘小龙 基于均相时间分辨荧光的检测重金属含量的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1839960A1 (ru) * 1987-01-19 2006-06-20 Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи АМН Штамм бактерий francisella tularensis для приготовления живой вакцины против туляремийной инфекции
WO1998014587A1 (en) * 1996-10-04 1998-04-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEAL TH AND HUMAN SERVICES Inhibition of hiv replication using soluble tat peptide analogs
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
GB0214942D0 (en) * 2002-06-28 2002-08-07 Secr Defence Immunogenic proteins and DNA encoding these

Also Published As

Publication number Publication date
EP2033655B1 (de) 2010-11-10
EP2033655A1 (de) 2009-03-11
DE602007010459D1 (de) 2010-12-23

Similar Documents

Publication Publication Date Title
TW200714283A (en) Method and composition for treating peripheral vascular diseases
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
ATE543910T1 (de) Verfahren und materialien zur herstellung von simvastatin und verwandten verbindungen
DE602006014949D1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
EP2100614B8 (de) Antikörper gegen PDGFR-alpha zur Verwendung bei der Behandlung von Tumoren
ATE540702T1 (de) Verfahren für die überprüfbare inaktivierung von pathogenen in einem biologischen fluid durch bestrahlung
CY1115566T1 (el) Παραγωγα phenoxypyridinyl amide και η χρηση τους στην θεραπεια καταστασεων ασθενειας με την μεσολαβηση της pde4
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
DE602006007808D1 (de) Vorrichtung, verfahren und verwendung zur behandlung von neuropathie mit stickoxid
MX2009009738A (es) Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento.
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
TW200716141A (en) Compositions and methods for treatment for neoplasms
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
EA200970718A1 (ru) Лиганд-модифицированные полиоксогидроксидные материалы с ионами металла, их применение и способы их получения
ATE487487T1 (de) Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämie
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
DE602006008583D1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
ATE549023T1 (de) Formulierungen mit jorumycin-, renieramycin-, safracin- oder saframycin-verwandten verbindungen und einen disaccharide zur behandlung von proliferativen erkrankungen
DE602005015697D1 (de) Te zur behandlung von alzheimer-krankheit
FI20060246A0 (fi) Uusi kasvua stimuloiva proteiini ja sen käyttö
ATE516290T1 (de) Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties